Updates on the treatment of lupus nephritis - PubMed

Affiliations

• PMID: 21051743
• DOI: 10.1681/ASN.2010050472

Review

Updates on the treatment of lupus nephritis

Andrew S Bomback et al. J Am Soc Nephrol. 2010 Dec.

Abstract

The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy-induction and maintenance-is widely accepted. The histopathologic classification of lupus nephritis continues to guide therapy, and treatment for all major classes of lupus nephritis has seen some shift in management during this time. New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have been advanced to reduce toxicity without sacrificing efficacy of therapy. Mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for induction therapy of both proliferative and membranous lupus nephritis. Combination induction treatment with multiple agents has also been successful. Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed. Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials.

Similar articles

• Sequential therapies for proliferative lupus nephritis.

  Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Contreras G, et al. N Engl J Med. 2004 Mar 4;350(10):971-80. doi: 10.1056/NEJMoa031855. N Engl J Med. 2004. PMID: 14999109 Clinical Trial.

• Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.

  Contreras G, Tozman E, Nahar N, Metz D. Contreras G, et al. Lupus. 2005;14 Suppl 1:s33-8. doi: 10.1191/0961203305lu2115oa. Lupus. 2005. PMID: 15803929 Clinical Trial.

• Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.

  Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R. Mejía-Vilet JM, et al. J Rheumatol. 2015 Nov;42(11):2082-91. doi: 10.3899/jrheum.150395. Epub 2015 Sep 15. J Rheumatol. 2015. PMID: 26373566

• Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.

  Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Zhu B, et al. Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. doi: 10.1093/ndt/gfm066. Epub 2007 Apr 3. Nephrol Dial Transplant. 2007. PMID: 17405792 Review.

• Recent progress in the treatment of lupus nephritis.

  Fanouriakis A, Krasoudaki E, Tzanakakis M, Boumpas DT. Fanouriakis A, et al. Mod Rheumatol. 2012 Nov;22(6):803-13. doi: 10.1007/s10165-012-0655-4. Epub 2012 May 15. Mod Rheumatol. 2012. PMID: 22584472 Review.

Cited by

• Knockout of the KH-Type Splicing Regulatory Protein Drives Glomerulonephritis in MRL-Fas^lpr Mice.

  Schmidtke L, Meineck M, Saurin S, Otten S, Gather F, Schrick K, Käfer R, Roth W, Kleinert H, Weinmann-Menke J, Pautz A. Schmidtke L, et al. Cells. 2021 Nov 14;10(11):3167. doi: 10.3390/cells10113167. Cells. 2021. PMID: 34831390 Free PMC article.

• The role of cytokine in the lupus nephritis.

  Iwata Y, Furuichi K, Kaneko S, Wada T. Iwata Y, et al. J Biomed Biotechnol. 2011;2011:594809. doi: 10.1155/2011/594809. Epub 2011 Oct 18. J Biomed Biotechnol. 2011. PMID: 22028590 Free PMC article. Review.

• RORγt expression in T_regs promotes systemic lupus erythematosus via IL-17 secretion, alteration of T_reg phenotype and suppression of Th2 responses.

  Kluger MA, Nosko A, Ramcke T, Goerke B, Meyer MC, Wegscheid C, Luig M, Tiegs G, Stahl RA, Steinmetz OM. Kluger MA, et al. Clin Exp Immunol. 2017 Apr;188(1):63-78. doi: 10.1111/cei.12905. Epub 2017 Jan 5. Clin Exp Immunol. 2017. PMID: 27880975 Free PMC article.

• Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization.

  Chen X, Wen Z, Xu W, Xiong S. Chen X, et al. PLoS One. 2013 Jun 5;8(6):e65542. doi: 10.1371/journal.pone.0065542. Print 2013. PLoS One. 2013. PMID: 23755248 Free PMC article.

• Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management.

  O'Grady J, Harty L, Mayer N, Critcher V, Ryan J. O'Grady J, et al. J Clin Med Res. 2015 Jun;7(6):490-4. doi: 10.14740/jocmr2133w. Epub 2015 Apr 8. J Clin Med Res. 2015. PMID: 25883715 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal